Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
Hepatitis C Virus Infection
Explore 12 assets in Hepatitis C Virus Infection →Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01756079CT.gov A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105) | — | Completed | — | — | — |
NCT01463956CT.gov Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation | — | Completed | — | — | — |
NCT00381017CT.gov Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) | — | Withdrawn | — | — | — |
NCT00018031CT.gov Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegylated-Interferon .Alfa. 2B (Peg-Ifn) (this asset) | Merck Sharp & Dohme LLC | Approved | BB · 70 |
| Veruprevir | AbbVie | P4 | A |
| Daclatasvir | MTI University | P4 | A |
| Glecaprevir | AbbVie | P3 | A |
| Pibrentasvir | AbbVie | P3 | A |
| Velpatasvir | Peking University People's Hospital | P4 | A |
| Sofosbuvir | Peking University People's Hospital | P4 | A |
| Ribavirin | Peking University People's Hospital | P4 | A |
| Ombitasvir | AbbVie | P3 | A |
+42 more in the Hepatitis C Virus Infection cohort
Other indications for Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Hepatitis C Virus Infection | — | P3 | BBB · 73 |
| Fibrotic Liver Disease | — | P3 | BB · 64 |
| Cirrhosis Of Liver | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegylated-Interferon .Alfa. 2B (Peg-Ifn) in Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegylated-interferon-alfa-2b-peg-ifn-hepatitis-c-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →